Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Collaborator: American Rhinologic Society
• Treatments: Sodium Tetradecyl Sulfate

Criteria

Inclusion Criteria:

• a clinical diagnosis of HHT based on the Curacoa Criteria

• age 18 and older

• cognitive ability and willingness to sign the study consent form and complete the study forms and questionnaires

Exclusion Criteria:

• previous sclerotherapy with Sodium Tetradecyl Sulfate